Table 2.

Change in study parameters during the follow-up period

Cohort	Dulaglutide, n = 30				Liraglutide, n = 30
Parameter	Baseline Mean ± SEM	Follow-up Mean ± SEM	Change Mean ± SEM	P	Baseline Mean ± SEM	Follow-up Mean ± SEM	Change Mean ± SEM	P
Body weight (kg)	87.17 ± 2.16	82.97 ± 2.05	−4.20 ± 0.47	< 0.001	89.43 ± 2.60	83.60 ± 2.35	−5.83 ± 0.87	< 0.001
BMI (kg/m2)	32.84 ± 0.77	31.312 ± 0 .68	−1.53 ± 0.21	< 0.001	34.92 ± 0.868	32.650 ± 0.77	−2.27 ± 0.33	< 0.001
SBP (mmHg)	134.30 ± 2.71	130.87 ± 2.49	−3.43 ± 2.97	0.258	137.83 ± 2.503	127.60 ± 2.07	−10.23 ± 2.36	< 0.001
DBP (mmHg)	80.73 ± 1.64	78.43 ± 0.914	− 2.30 ± 1.79	0.208	83.47 ± 1.587	80.67 ± 1.51	− 2.80 ± 1.85	0.141
FPG(mg/dl)	175.53 ± 11.45	133.67 ± 6.90	− 41.87 ± 12.72	0.003	160.13 ± 8.17	115.93 ± 5.69	− 44.20 ± 8.05	< 0.001
HbA1c (%)	8.43 ± 0.21	7.411 ± 0.15	−1.017 ± 0.22	< 0.001	8.49 ± 0.26	6.95 ± 0.21	− 1.547 ± 0.22	< 0.001